Oral Rigosertib Combined With Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukaemia: Effects in Treatment Naïve and Relapsed/ Refractory Patients
Azacitidine is the standard of care for higher risk myelodysplastic syndromes (MDS); however, only approximately 50% of patients respond, and those…